ClinicalTrials.gg
CompletedNCT01456260Updated May 8, 2014

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

A Phase 3 interventional study of TAK-438 and Placebo in Gastric Ulcers and Duodenal Ulcers, sponsored by Takeda. Completed at 97 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-05-08.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.

Enrollment
5th of 10
406 · median 320
Started
2011
with 3 others
Phase 3
8 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
Takeda

Among the 10 studies testing vonoprazan in Stomach Ulcer, this one is the 5th largest by enrollment, is one of 4 that started in 2011, is one of 8 in phase 3, and was the 1st registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Stomach Ulcer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant non-steroidal anti-inflammatory drug (NSAID) therapy in patients with a history of gastric or duodenal ulcer who require long-term therapy of NSAID.

03

Conditions studied

  • Gastric Ulcers
  • Duodenal Ulcers

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who require continuous NSAID therapy during the treatment period with the study drug
  2. Participants who have completed the preceding study
  3. Outpatient (including inpatient for examinations)

Exclusion criteria

Exclusion Criteria:

  1. Participants deemed to be ineligible to participate in the study by the principal investigator or investigator due to the occurrence of adverse events in the preceding study
  2. Participants who are scheduled to change the type and dosage regimen of NSAID
  3. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed during the preceding study
  4. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
  5. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
  6. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  7. Participants with a previous or current history of aspirin-induced asthma
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    TAK-438 10 mg QD

    Drug: TAK-438 · Drug: Placebo

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438 · Drug: Placebo

  • Active comparator
    Lansoprazole 15 mg QD

    Drug: Lansoprazole · Drug: Placebo

Interventions

  • TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.

  • DrugPlacebo

    Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.

  • TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.

  • DrugPlacebo

    Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.

  • Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.

    Also known as: AG-1749

  • DrugPlacebo

    TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through the last visit of study.

    Time frame: Up to 80 weeks.

Secondary outcomes

  1. Change from baseline in Laboratory values

    Time frame: Up to 80 weeks.

  2. Change from baseline in Electrocardiograms

    Time frame: Up to 80 weeks.

  3. Change from baseline in Vital signs

    Time frame: Up to 80 weeks.

  4. Change from baseline in Serum gastrin

    Time frame: Up to 80 weeks.

  5. Change from baseline in Pepsinogen I and II

    Time frame: Up to 80 weeks.

  6. Recurrence rate of gastric or duodenal ulcer

    Time frame: Up to 80 weeks.

07

Study locations

97 sites
  • Kasugai-shi, Aichi, Japan
  • Nagoya-shi, Aichi, Japan
  • Seto-shi, Aichi, Japan
  • Akita-shi, Akita, Japan
  • Funabashi-shi, Chiba, Japan
  • Ichihara-shi, Chiba, Japan
  • Nagareyama-shi, Chiba, Japan
  • Matsuyama-shi, Ehime, Japan
  • Niihama-shi, Ehime, Japan
  • Saijo-shi, Ehime, Japan
  • Fukui-shi, Fukui, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Itoshima-shi, Fukuoka, Japan
  • Kitakyusyu-shi, Fukuoka, Japan
  • Munakata-shi, Fukuoka, Japan
  • Onga-gun, Fukuoka, Japan
  • Tagawa-shi, Fukuoka, Japan
  • Yukuhashi-shi, Fukuoka, Japan
  • Fukushima-shi, Fukushima, Japan
  • Koriyama-shi, Fukushima, Japan
  • Mebashi-shi, Gunma, Japan
  • Takasaki-shi, Gunma, Japan
  • Fukuyama-shi, Hiroshima, Japan
  • Hatsukaichi-shi, Hiroshima, Japan
  • Higashihirosima-shi, Hiroshima, Japan
  • Asahikawa-shi, Hokkaido, Japan
  • Hakodate-shi, Hokkaido, Japan
  • Obihiro-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Sunagawa-shi, Hokkaido, Japan
  • Tomakomai-shi, Hokkaido, Japan
  • Akashi-shi, Hyogo, Japan
  • Himeji-shi, Hyogo, Japan
  • Itami-shi, Hyogo, Japan
  • Kako-gun, Hyogo, Japan
  • Kato-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Higashiibaragi-gun, Ibaragi, Japan
  • Koga-shi, Ibaragi, Japan
  • Mito-shi, Ibaragi, Japan
  • Hakusan-shi, Ishikawa, Japan
  • Komatsu-shi, Ishikawa, Japan
  • Takamatsu-shi, Kagawa, Japan
  • Kamakura-shi, Kanagawa, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Uji-shi, Kyoto, Japan
  • Tsu-shi, Mie, Japan
  • Sendai-shi, Miyagi, Japan
  • Matsumoto-shi, Nagano, Japan
  • Nagano-shi, Nagano, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Ikoma-shi, Nara, Japan
  • Nara-shi, Nara, Japan
  • Nigata-shi, Nigata, Japan
  • Beppu-shi, Oita, Japan
  • Oita-shi, Oita, Japan
  • Yuhu-shi, Oita, Japan
  • Kurashiki-shi, Okayama, Japan
  • Higashiosaka-shi, Osaka, Japan
  • Moriguchi-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Osakasayama-shi, Osaka, Japan
  • Tondabayashi-shi, Osaka, Japan
  • Ogi-shi, Saga, Japan
  • Ageo-shi, Saitama, Japan
  • Hiki-gun, Saitama, Japan
  • Kasukabe-shi, Saitama, Japan
  • Kumagaya-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Sayama-shi, Saitama, Japan
  • Toda-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Otsu-shi, Shiga, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Naruto-shi, Tokushima, Japan
  • Adachi-ku, Tokyo, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Hachiouji-shi, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Musashimurayama-shi, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Sumida-ku, Tokyo, Japan
  • Yonago-shi, Tottori, Japan
  • Tonami-shi, Toyama, Japan
  • Toyama-shi, Toyama, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Ube-shi, Yamaguchi, Japan
08

References and documents

Publications

  • Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7. PubMed 28988197 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2011
First posted
Oct 20, 2011
Start
Sep 2011
CompletionActual
Dec 2013
Last update
May 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01456260
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 20, 2011
Start date
Sep 2011
Completion
Dec 2013
Last update
May 8, 2014

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion